Related Experiment Video
Updated: Aug 13, 2025
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
Novel Therapeutic Approaches Targeting Post-Translational Modifications in Lung Cancer
Maria Francesca Baietti1, Raj Nayan Sewduth2
1TRACE, Laboratory for RNA Cancer Biology, Department of Oncology, KU Leuven, Herestraat 49, 3000 Leuven, Belgium.
Abstract:
Lung cancer is one of the most common cancers worldwide. It consists of two different subtypes: non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Despite novel therapeutic options such as immunotherapy, only 20% of lung cancer patients survive the disease after five years. This low survival rate is due to acquired drug resistance and severe off-target effects caused by currently used therapies. Identification and development of novel and targeted therapeutic approaches are urgently required to improve the standard of care for lung cancer patients. Here, we describe the recent development of novel drug-delivery approaches, such as adenovirus, lipid nanoparticles, and PROTACs, that have been tested in clinical trials and experimentally in the context of fundamental research. These different options show that it is now possible to target protein kinases, phosphatases, ubiquitin ligases, or protein modifications directly in lung cancer to block disease progression. Furthermore, the recent acceptance of RNA vaccines using lipid nanoparticles has further revealed therapeutic options that could be combined with chemo-/immunotherapies to improve current lung cancer therapies. This review aims to compare recent advances in the pharmaceutical research field for the development of technologies targeting post-translational modifications or protein modifiers involved in the tumorigenesis of lung cancer.
Insights
Novel drug-delivery systems, including lipid nanoparticles and PROTACs, offer new ways to target lung cancer (NSCLC and SCLC) and overcome treatment resistance, potentially improving patient survival rates.
Area of Science:
- Oncology
- Pharmacology
- Biotechnology
Background:
- Lung cancer remains a leading cause of cancer mortality worldwide, with subtypes including non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).
- Current therapies, including immunotherapy, have limited efficacy, with a 5-year survival rate of only 20%, often due to drug resistance and off-target effects.
- There is a critical need for innovative and targeted therapeutic strategies to enhance lung cancer treatment outcomes.
Purpose of the Study:
- To review and compare recent advancements in drug-delivery technologies for lung cancer therapy.
- To explore novel approaches targeting protein modifications and modifiers involved in lung cancer development.
- To assess the potential of new technologies to overcome current treatment limitations.
Main Methods:
- Review of recent clinical trials and fundamental research on novel drug-delivery systems.
- Analysis of technologies such as adenovirus, lipid nanoparticles, and Proteolysis-Targeting Chimeras (PROTACs).
- Examination of strategies targeting protein kinases, phosphatases, ubiquitin ligases, and post-translational modifications.
Main Results:
- Emerging drug-delivery systems show promise in directly targeting key molecules in lung cancer cells.
- Lipid nanoparticles, validated by RNA vaccines, offer a platform for combination therapies with chemotherapy and immunotherapy.
- PROTACs and other targeted approaches demonstrate potential to block lung cancer progression by modulating specific proteins.
Conclusions:
- Novel drug-delivery technologies represent a significant step forward in developing targeted lung cancer therapies.
- These approaches have the potential to overcome acquired drug resistance and reduce off-target effects, thereby improving patient survival.
- Future research focusing on these advanced pharmaceutical strategies could revolutionize lung cancer treatment.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...